Larimar Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Larimar is a clinical-stage biotechnology company developing nomlabofusp, a candidate intended to deliver frataxin to patients with Friedreich’s ataxia (FA). It has no product revenue and expects no commercial product revenue for several years, if ever.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $12.9 million | $4.6 million |
| General and administrative expense | $3.8 million | $3.1 million |
| Total operating expenses | $16.7 million | $7.6 million |
| Net loss | $14.7 million | $6.5 million |
| Net loss per share | $0.27 | $0.15 |
| Net cash used in operations | $10.4 million | $7.6 million |
| Cash and cash equivalents | $110.1 million | $26.7 million at Dec. 31, 2023 |
| Marketable securities | $128.9 million | $60.0 million at Dec. 31, 2023 |
| Total assets / liabilities | $248.2 million / $17.4 million | $95.9 million / $14.2 million at Dec. 31, 2023 |
Margins are not meaningful because the company has no revenue. Other income was $2.1 million, primarily interest income, versus $1.1 million in Q1 2023. Cash, cash equivalents and marketable securities totaled approximately $239.0 million at quarter-end; restricted cash of $1.3 million is additional. The company reported no borrowings; liabilities primarily include operating lease obligations, with $5.3 million present value of lease liabilities.
Material changes and financing
- Operating expenses rose $9.1 million year over year, and net loss widened $8.1 million. R&D increased $8.4 million, mainly from nomlabofusp manufacturing costs (+$5.7 million), clinical costs (+$1.0 million, including the OLE), and personnel (+$1.0 million).
- In February 2024, Larimar sold 19.7 million shares at $8.74 per share, receiving approximately $161.8 million net. The offering materially increased the share count: 63.8 million shares were outstanding at March 31, versus 43.9 million at December 31, 2023.
- Investing activities used $68.4 million, primarily reflecting purchases of marketable securities; financing activities provided $162.2 million. The quarter-end increase in cash, cash equivalents and restricted cash was $83.4 million.
Outlook, development and risks
- Management expects existing cash, cash equivalents and marketable securities to fund forecasted operations into 2026. It expects continued operating losses and rising R&D and G&A expenses, and may seek additional financing.
- Larimar reported positive topline results from its completed four-week Phase 2 dose-exploration study: nomlabofusp was generally well tolerated, showed predictable pharmacokinetics, and increased FXN levels in evaluated tissues in a dose-dependent manner. The filing describes 25 mg and 50 mg cohorts; these findings are preliminary clinical evidence, not proof of efficacy or approval.
- The FDA’s partial clinical hold remains relevant. Additional U.S. trials and dose escalation in the OLE depend on FDA review. A 2021 full hold followed reported mortalities at the highest doses in a 26-week non-human-primate toxicology study; the FDA later lifted the full hold but imposed a partial hold.
- The OLE began dosing its first patient in March 2024. Interim data are expected in Q4 2024. Management is pursuing an accelerated-approval approach using tissue FXN levels as a potential surrogate endpoint and targets a BLA submission in the second half of 2025; timing and pathway depend on FDA feedback and supporting data.
- Key risks include clinical and regulatory uncertainty, trial enrollment and timing, manufacturing scale-up and supply, dependence on third parties, future financing needs, and the possibility that additional data or studies delay development. The filing reports no material pending or threatened litigation.
- After quarter-end, on May 9, 2024, Larimar entered an ATM sales agreement allowing up to $100 million of common stock sales, subject to registration effectiveness. Sales are optional and could dilute shareholders.
Important facts for investors to verify
- Whether FDA review changes the partial-hold status, permits dose escalation or additional trials, and supports the proposed accelerated-approval strategy.
- The OLE’s enrollment, safety, FXN and clinical data, including the expected Q4 2024 interim update.
- Progress toward the targeted second-half 2025 BLA submission and the evidence FDA will require for any surrogate endpoint.
- Cash burn against the stated runway into 2026, future financing plans, and any use of the $100 million ATM facility.
- Manufacturing readiness and the implications of the prior non-human-primate toxicology mortalities for long-term dosing.